

05-08-06

162
162
162

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Barbara Scott et al

Serial No.: 09/777,554

ART UNIT: 1626

Filed: February 6, 2001

EXAMINER: Shiao, Rei Tsang

Entitled: BENZOTHAZOLE DERIVATIVES

Atty. Docket No.: BBC-077/A

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence and the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. **EQ556925836US**, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

May 5, 2006
date of mailing and signature

Daphne Miller
Daphne Miller

TRANSMITTAL LETTER

Sir/Madam:

Transmitted herewith are: ☒ An Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98; ☒ Form PTO-1449 Information Disclosure Statement; ☒ A photocopy of each reference cited; and ☒ An Acknowledgement Postcard to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

☒ A fee for additional claims is not required.

☐ A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEE DUE
TOTAL CLAIMS				× \$50	=
INDEPENDENT				× \$200	=
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				+\$280	= 0.00
TOTAL FEES DUE					=

PAYMENT OF ADDITIONAL FEES

- [X]** The Commissioner is hereby authorized to charge payment of \$180.00 as required under 37 CFR 1.17(p) in connection with the paper(s) transmitted herewith to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

PETITION FOR EXTENSION OF TIME

- []** Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith:
- []** \$120.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
 - []** \$450.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
 - []** \$1,020.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
 - []** \$1,590.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4);
 - []** \$2,160.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5);
- [X]** The Commissioner is hereby authorized to charge payment of any fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.


Respectfully submitted,



Gayle B. O'Brien
Agent for Applicants
Reg. No. 48,812
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
Tel: (508) 688-8053
Fax: (508) 688-8110

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Barbara Scott et al.
Serial No. : 09/777,554
Filed : February 6, 2001
Entitled : BENZOTHIAZOLE
DERIVATIVES



ART UNIT: 1626
EXAMINER: Shiao, Rei Tsang

Attorney Docket No. BBC-077/A

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence and the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EQ556925836US in an envelope addressed to the Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

May 5, 2006
date of mailing and signature

Daphne Miller
Daphne Miller

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.56, 1.97 AND 1.98**

Sir/Madam:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR § 1.97 and 1.98 for the above-identified application. This Information Disclosure Statement was originally submitted by Applicants February 12, 2002 but was not received by the US PTO. Applicants makes the following publications of record in the above-identified application.

U.S. PATENT DOCUMENTS

U.S. 4,966,849
U.S. 5,217,999
U.S. 5,302,606
U.S. 5,330,992

05/10/2006 BARRAH1 00000102 010025 09777554
01 FC:1806 180.00 DA

Other Publications

WO 91/15495 A1
WO 92/20642 A1
WO 92/21660 A1
WO 94/03427 A1
WO 94/10202 A1
WO 94/14808 A1
EP 566 226 B1
WO 97/22596 A1
WO 97/34876 A1
WO97/40830 A1
WO 97/40831 A1
WO 97/42187 A1
WO 98/07832 A1

Expert Opin. Ther. Pat 8(4): 475-479 (1998)
Achen et al., PNAS USA 95(2): 548-553 (1998)
Aplin et al., Journal of Neurochemistry, 67:699-707 (1996)
Armstrong, Clinical Infectious Diseases, 16:1-7 (1993)
Badger et al., The J. of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996)
Baeuerle et al., Annual Review of Immunology, 12:141-179 (1994)
Beg et al., Science, 274:782-784 (1996)
Bolen, Oncogene 8:2025-2031 (1993)
Borthwick et al., Biochemical & Biophysical Research Communications, 210:738-745 (1995)
Brickell, Critical Reviews in Oncogenesis, 3:401-406 (1992)
Brown et al., Regulation of Angiogenesis (ed. L.D. Golberg and E.M. Rosen), 233-169 (1997)
Buchdunger et al., PNAS USA, 92:2258-2262 (1995)
Courtneidge, Seminars in Cancer Biology, 5:236-246 (1994)
Cowburn, Curr. Opin. Struct. Biol., 7(6):835-838 (1997)
De Vries et al., Science 255:989-991 (1992)
Draetta, Trends in Cell Biology, 3:287-289 (1993)
Ducommun et al., EMBO Journal, 10:3311-3319 (1991)
Fantl et al., Cell 69:413-423 (1992)
Ferrara et al., J. Cell. Biochem. 47:211-218 (1991)
Ferrara et al., (ed. L.D. Goldberg and E.M. Rosen), 209-232 (1997)
Ferrara et al., Endocrine Reviews 18(1):4-25 (1997)

Gautier et al., Nature 339:626-629 (1989)
Gilbert, Neuron 9:1-13 (1992)
Girard et al., Cell, 67:1169-1179 (1991)
Gould et al., Nature, 342:39-45 (1989)
He et al., J. of Virology, 71:405-411 (1997)
Hosoi et al., J. of Biochemistry (Tokyo), 117:741-749 (1995)
Hunter et al., Cell, 79:573-582 (1994)
Jakeman et al., Endocrinology 133:848-859 (1993)
Jellinek et al., Biochemistry 33:10450-56 (1994)
Kendall et al., Proc. Natl. Acad. Sci 90:10705-09 (1994)
Kim et al., Nature 362:841-844 (1993)
Kinsella, et al., Exp. Cell Res. 199:56-62 (1992)
Klagsburn et al, Cytokine & Growth Factor Reviews 7:259-270 (1996)
Koch et al, Science 252:668-678 (1991)
Kohn et al., J. of Cellular Biochemistry, 54:440-452 (1994)
Kolch et al, Breast Cancer Research and Treatment 36:139-155 (1995)
Korpelainen et al., Curr. Opin. Cell Biol., 1:159-164 (1998)
Krek et al., EMBO Journal 10:3331-3341 (1991)
Lees, Current Opinion in Cell Biology, 7:773-780 (1995)
Lymboussaki et al., Am. J. Pathol. 153(2):395-403 (1998)
Maglionet et al., Oncogene 8:925-31 (1993)
Mariani et al., Proc. Am. Assoc. Cancer Res. 35:2268 (1994)
Matsushime et al., Molecular & Cellular Biology, 14:2066-2076 (1994)
Matthews et al., PNAS USA 88:9026-30 (1991)
Meyer et al., EMBO J. 18(2):363-374 (1999)
Migdal et al., J. Biol. Chem. 273 (35):22272-22278 (1998)
Millauer et al., Cell 72:835-846 (1993)
Murray et al., Nature, 339:275-280 (1989)
Mustonen et al., J. Cell Biol. 129:895-898 (1995)
Myers et al., Bioorg. Med. Chem. Lett. 7:417-420 (1997)
Myers et al., Bioorganic & Medicinal Chem. Lett. 7:421-424 (1997)
Oelrichet et al., Oncogene 8(1):11-15 (1993)

- Ogawa et al, J. Biol. Chem 273(47):31273-31282 (1998)
- Ohtsubo et al., Science, 259:1908-1912 (1993)
- Osmani et al., Cell, 67:283-291 (1991)
- Osmani et al., EMBO Journal, 10:2669-2679 (1991)
- Pagano et al, EMBO Journal, 11:961-971 (1992)
- Park et al, J. Biol. Chem. 269:25646-54 (1994)
- Perkins et al., Science, 275:523-527 (1997)
- Pines, Current Opinion in Cell Biology, 4:144-148 (1992)
- Pines, Trends in Biochemical Sciences, 18:195-197 (1993)
- Powis, Pharmacology & Therapeutics, 62:57-95 (1994)
- Quelle et al., Genes & Development, 7:1559-1571 (1993)
- Resnitzky et al, Molecular & Cellular Biology, 14:1669-1679 (1994)
- Ristimäki et al, J. Biol. Chem. 273(14):8413-8418 (1998)
- Rosenblatt et al., Proc. Nat Acad. Sc. USA, 89:2824-2828 (1992)
- Schlessinger et al., Neuron 9:383-391 (1992)
- Shawver et al., Drug Discovery Today, 2:50-63 (1997)
- Sherr, Cell, 73:1059-1065 (1993)
- Shibuya et al., Oncogene 5:519-524 (1990)
- Shoelson, Curr. Opin. Chem. Biol. 1(2):227-234 (1997)
- Solomon et al., Cell, 63:1013-1024 (1990)
- Solomon et al., Molecular Biology of the Cell, 13-27 (1992)
- Songyang et al, Cell 72:767-778 (1993)
- Songyang et al, Mol. Cell. Biol. 14:2777-2785 (1994)
- Staunton et al., Cell 61:243-254 (1990)
- Stone et al., Cancer Research, 56:3199-3202 (1996)
- Takano et al., Mol. Bio. Cell 4:358A (1993)
- Tanaka et al., Nature, 383:528-531 (1996)
- Terman et al., Oncogene 6:1677-83 (1991)
- Terman et al., Biochem. Biophys. Res. Comm, 187:1579-86 (1992)
- Ullrich et al., Cell 61:203-212 (1990)
- Van Antwerp et al, Science, 274:787-789 (1996)
- Vousden, FASEB Journal, 7:872-879 (1993)

Walker et al., Nature, 354:314-317 (1991)

Wang et al, Science, 274:784-787 (1996)

Williams, Diabetologia 40:S118-120 (1997)

Witzenbichlet et al., Am. J. Pathol., 153(2):381-394 (1998)

Wright et al., J. Cellular Phys. 152:448-57 (1992)

Yarden et al., Ann. Rev. Biochem 57:443-478 (1998)

Zindy et al., Biochemical & Biophysical Research Comm., 182:1144-1154 (1992)

Olofsson et al., PNAS USA 95:11709-11714 (1998)

Walker et al., Nature, 354:314-317 (1991)

Wang et al, Science, 274:784-787 (1996)

Williams, Diabetologia 40:S118-120 (1997)

Witzenbichlet et al., Am. J. Pathol., 153(2):381-394 (1998)

Wright et al., J. Cellular Phys. 152:448-57 (1992)

Yarden et al., Ann. Rev. Biochem 57:443-478 (1998)

Zindy et al., Biochemical & Biophysical Research Comm., 182:1144-1154 (1992)

Olofsson et al., PNAS USA 95:11709-11714 (1998)

Respectfully submitted,



Gayle B. O'Brien
Agent for Applicants
Reg. No. 48,812
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
Tel: (508) 688-8053
Fax: (508) 688-8110

APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,966,849	10/90	Vallee et al.	435	199	
	A2	5,217,999	06/93	Levitzki et al.	514	613	
	A3	5,302,606	04/94	Spada et al.	514	357	
	A4	5,330,992	07/94	Eissenstat et al.	514	312	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A5	WO 91/15495 A1	10/91	PCT				
	A6	WO 92/20642 A1	11/92	PCT				
	A7	WO 92/21660 A1	12/92	PCT				
	A8	WO 94/03427 A1	02/94	PCT				
	A9	WO 94/10202 A1	05/94	PCT				
	A10	WO 94/14808 A1	07/94	PCT				
	A11	EP 566 226 B1	11/95	EPO				
	A12	WO 97/22596 A1	06/97	PCT				
	A13	WO 97/34876 A1	09/97	PCT				
	A14	WO97/40830 A1	11/97	PCT				
	A15	WO 97/40831 A1	11/97	PCT				
	A16	WO 97/42187 A1	11/97	PCT				
	A17	WO 98/07832 A1	02/98	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


	A18	<i>Expert Opin. Ther. Pat.</i> 8(4): 475-478 (1998)
	A19	Achen <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>PNAS USA</i> 95(2): 548-553 (1998)
	A20	Aplin <i>et al.</i> , "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," <i>Journal of Neurochemistry</i> , 67:699-707 (1996)
	A21	Armstrong, "Treatment of opportunistic fungal infections," <i>Clinical Infectious Diseases</i> , 16:1-7. (1993)
	A22	Badger <i>et al.</i> , "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 279:1453-1461 (1996)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


B1	Baeuerle <i>et al.</i> , "Function and activation of NF-kappa B in the immune system," <i>Annual Review of Immunology</i> , 12:141-179 (1994)
B2	Beg <i>et al.</i> , "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," <i>Science</i> , 274:782-784 (1996)
B3	Bolen, "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> 8:2025-2031 (1993)
B4	Borthwick <i>et al.</i> , "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts," <i>Biochemical & Biophysical Research Communications</i> , 210:738-745 (1995)
B5	Brickell, "The p60c-src family of protein-tyrosine kinases: structure, regulation, and function," <i>Critical Reviews in Oncogenesis</i> , 3:401-406 (1992)
B6	Brown <i>et al.</i> , <i>Regulation of Angiogenesis</i> (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997)
B7	Buchdunger <i>et al.</i> , "Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," <i>PNAS USA</i> , 92:2258-2262 (1995)
B8	Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," <i>Seminars in Cancer Biology</i> , 5:236-246 (1994)
B9	Cowburn, "Peptide recognition by PTB and PDZ domains," <i>Curr. Opin. Struct. Biol.</i> , 7(6):835-838 (1997)
B10	De Vries <i>et al.</i> , "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," <i>Science</i> 255:989-991 (1992)
B11	Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," <i>Trends in Cell Biology</i> , 3:287-289 (1993)
B12	Ducommun <i>et al.</i> , "cdc2 phosphorylation is required for its interaction with cyclin," <i>EMBO Journal</i> , 10:3311-3319 (1991)
B13	Fantl <i>et al.</i> , "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways," <i>Cell</i> 69:413-423 (1992)
B14	Ferrara <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cell. Biochem.</i> 47:211-218 (1991)
B15	Ferrara <i>et al.</i> , "Vascular endothelial growth factor: Basic biology and clinical implications," in <i>Regulation of Angiogenesis</i> (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997)
B16	Ferrara <i>et al.</i> , "The biology of vascular endothelial growth factor," <i>Endocrine Reviews</i> 18(1): 4-25 (1997)
B17	Gautier <i>et al.</i> , "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," <i>Nature</i> 339:626-629 (1989)
B18	Gilbert, "Horizontal integration and cortical dynamics," <i>Neuron</i> 9:1-13 (1992)
B19	Girard <i>et al.</i> , "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," <i>Cell</i> , 67:1169-1179 (1991)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


		Gould <i>et al.</i> , "Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis," <i>Nature</i> , 342:39-45 (1989)
	C2	He <i>et al.</i> , "The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines," <i>Journal of Virology</i> , 71:405-411 (1997)
	C3	Hosoi <i>et al.</i> , "Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract," <i>Journal of Biochemistry (Tokyo)</i> , 117:741-749 (1995)
	C4	Hunter <i>et al.</i> , "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," <i>Cell</i> , 79:573-582 (1994)
	C5	Jakeman <i>et al.</i> , "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," <i>Endocrinology</i> 133: 848-859 (1993)
	C6	Jellinek, <i>et al.</i> , "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor," <i>Biochemistry</i> 33:10450-56 (1994)
	C7	Kendall <i>et al.</i> , "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <i>Proc. Natl. Acad. Sci</i> 90:10705-09 (1994)
	C8	Kim <i>et al.</i> , "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," <i>Nature</i> 362:841-844 (1993)
	C9	Kinsella, <i>et al.</i> "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," <i>Exp. Cell Res.</i> 199:56-62 (1992)
	C10	Klagsburn <i>et al.</i> , "Vascular endothelial growth factor and its receptors," <i>Cytokine & Growth Factor Reviews</i> 7: 259-270 (1996)
	C11	Koch <i>et al.</i> , "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," <i>Science</i> 252:668-678 (1991)
	C12	Kohn <i>et al.</i> , "Cell cycle control and cancer chemotherapy," <i>Journal of Cellular Biochemistry</i> , 54:440-452 (1994)
	C13	Kolch <i>et al.</i> , "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis," <i>Breast Cancer Research and Treatment</i> 36: 139-155 (1995)
	C14	Korpelainen <i>et al.</i> , "Signaling angiogenesis and lymphangiogenesis," <i>Curr. Opin. Cell Biol.</i> , 10:159-164 (1998)
	C15	Krek <i>et al.</i> , "Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," <i>EMBO Journal</i> , 10:3331-3341 (1991)
	C16	Lees, "Cyclin dependent kinase regulation," <i>Current Opinion in Cell Biology</i> , 7:773-780 (1995)
	C17	Lymboussaki <i>et al.</i> , "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," <i>Am. J. Pathol.</i> 153(2): 395-403 (1998)
	C18	Maglione <i>et al.</i> "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-31 (1993)
	C19	Mariani, <i>et al.</i> , "inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <i>Proc. Am. Assoc. Cancer Res.</i> 35:2268 (1994)
	C20	Matsushime <i>et al.</i> , "D-type cyclin-dependent kinase activity in mammalian cells," <i>Molecular & Cellular Biology</i> , 14:2066-2076 (1994)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 6, 2001

GROUP

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

D1	Matthews <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>PNAS USA</i> , 88:9026-30 (1991)
D2	Meyer <i>et al.</i> , "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases," <i>EMBO J.</i> 18(2):363-374 (1999)
D3	Migdal <i>et al.</i> , "Neuropilin-1 is a placenta growth factor-2 receptor," <i>J. Biol. Chem.</i> 273 (35): 22272-22278 (1998)
D4	Millauer <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993)
D5	Murray <i>et al.</i> , "Cyclin synthesis drives the early embryonic cell cycle," <i>Nature</i> , 339:275-280 (1989)
D6	Mustonen <i>et al.</i> , "Endothelial receptor tyrosine kinases involved in angiogenesis," <i>J. Cell Biol.</i> 129:895-898 (1995)
D7	Myers <i>et al.</i> , "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56 ^{lck} and EGF-R tyrosine kinase activity," <i>Bioorg. Med. Chem. Lett.</i> 7:417-420 (1997)
D8	Myers <i>et al.</i> , "The synthesis and sar of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity," <i>Bioorganic & Medicinal Chemistry Letters</i> , 7:421-424 (1997)
D9	Oelrichs <i>et al.</i> , "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo," <i>Oncogene</i> 8(1):11-15 (1993)
D10	Ogawa <i>et al.</i> , "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain," <i>J. Biol. Chem.</i> 273(47): 31273-31282 (1998)
D11	Ohtsubo <i>et al.</i> , "Cyclin-dependent regulation of G1 in mammalian fibroblasts," <i>Science</i> , 259:1908-1912 (1993)
D12	Osmani <i>et al.</i> , "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in <i>A. nidulans</i> ," <i>Cell</i> , 67:283-291 (1991)
D13	Osmani <i>et al.</i> , "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint," <i>EMBO Journal</i> , 10:2669-2679 (1991)
D14	Pagano <i>et al.</i> , "Cyclin A is required at two points in the human cell cycle," <i>EMBO Journal</i> , 11:961-971 (1992)
D15	Park <i>et al.</i> , "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR," <i>J. Biol. Chem.</i> 269:25646-54 (1994)
D16	Perkins <i>et al.</i> , "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator," <i>Science</i> , 275:523-527 (1997)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO BBI-6077CP	SERIAL NO. 09/777,554
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Cusack, K. P. et al.	
		FILING DATE February 8, 2001	GROUP

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

E1	Pines, "Cell proliferation and control," <i>Current Opinion in Cell Biology</i> , 4:144-148 (1992)
E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)
E3	Powis, "Signalling pathways as targets for anticancer drug development," <i>Pharmacology & Therapeutics</i> , 62:57-95 (1994)
E4	Quelle et al., "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," <i>Genes & Development</i> , 7:1559-1571 (1993)
E5	Resnitzky et al., "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," <i>Molecular & Cellular Biology</i> , 14:1669-1679 (1994)
E6	Ristimaki et al., "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," <i>J. Biol. Chem.</i> 273(14):8413-8418 (1998)
E7	Rosenblatt et al., "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A," <i>Proc. Nat Acad. Sc. USA</i> , 89:2824-2828 (1992)
E8	Schlessinger et al., "Growth factor signaling by receptor tyrosine kinases," <i>Neuron</i> 9:383-391 (1992)
E9	Shawver et al., "Receptor tyrosine kinases as targets for inhibition of angiogenesis," <i>Drug Discovery Today</i> , 2:50-63 (1997)
E10	Sherr, "Mammalian G1 cyclins," <i>Cell</i> , 73:1059-1065 (1993)
E11	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <i>Oncogene</i> 5:519-524 (1990)
E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," <i>Curr. Opin. Chem. Biol.</i> 1(2): 227-234 (1997)
E13	Solomon et al., "Cyclin activation of p34cdc2," <i>Cell</i> , 63:1013-1024 (1990)
E14	Solomon et al., "Role of phosphorylation in p34cdc2 activation: identification of an activating kinase," <i>Molecular Biology of the Cell</i> , 3:13-27 (1992)
E15	Songyang et al., "SH2 domains recognize specific phosphopeptide sequences," <i>Cell</i> 72:767-778 (1993)
E16	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," <i>Mol. Cell. Biol.</i> 14:2777-2785 (1994)
E17	Staunton et al., "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," <i>Cell</i> 61:243-254 (1990)
E18	Stone et al., "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," <i>Cancer Research</i> , 56:3199-3202 (1996)
E19	Takano, et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," <i>Mol. Bio. Cell</i> 4:358A (1993)
E20	Tanaka et al., "c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption," <i>Nature</i> , 383:528-531 (1996)
Examiner _____ Date Considered _____	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



LIST OF PUBLICATIONS
(Use several sheets)
MAY 05 2006
PATENT & TRADEMARK OFFICE

[illegible]